» Articles » PMID: 32016459

Lithium Chloride Increases Sensitivity to Photon Irradiation Treatment in Primary Mesenchymal Colon Cancer Cells

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2020 Feb 5
PMID 32016459
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide. It is also the second most common cause of cancer‑associated mortality; it accounted for about 9.2% of all cancer deaths in 2018, most of which were due to resistance to therapy. The main treatment for CRC is surgery, generally associated with chemotherapy, radiation therapy and combination therapy. However, while chemo‑radiotherapy kills differentiated cancer cells, mesenchymal stem‑like cells are resistant to this treatment, and this can give rise to therapy‑resistant tumors. Our previous study isolated T88 primary colon cancer cells from a patient with sporadic colon cancer. These cells exhibited mesenchymal and epithelial features, high levels of epithelial‑to‑mesenchymal transition transcription factors, and stemness markers. In addition, it was revealed that lithium chloride (LiCl), a specific glycogen synthase kinase (GSK)‑3β inhibitor, induced both the mesenchymal‑to‑epithelial transition and differentiation, and also reduced cell migration, stemness features and cell plasticity in these primary colon cancer cells. The aim of the present study was to investigate the effect of LiCl treatment on the viability of primary colon cancer cells exposed to 7 Gy delivered by high‑energy photon beams, which corresponds to 6 megavolts of energy. To achieve this aim, the viability of irradiated T88 cells was compared with that of irradiated T88 cells pre‑treated with LiCl. As expected, it was observed that LiCl sensitized primary colon cancer cells to high‑energy photon irradiation treatment. Notably, the decrease in cell viability was greater with combined therapy than with irradiation alone. To explore the molecular basis of this response, the effect of LiCl on the expression of Bax, p53 and Survivin, which are proteins involved in the apoptotic mechanism and in death escape, was analyzed. The present study revealed that LiCl upregulated the expression of pro‑apoptotic proteins and downregulated the expression of proteins involved in survival. These effects were enhanced by high‑energy photon irradiation, suggesting that LiCl could be used to sensitize colon cancer cells to radiation therapy.

Citing Articles

Unrevealing Lithium Repositioning in the Hallmarks of Cancer: Effects of Lithium Salts (LiCl and LiCO) in an In Vitro Cervical Cancer Model.

Garcia-Acosta J, Castillo-Montoya A, Rostro-Alonso G, Villegas-Vazquez E, Quintas-Granados L, Sanchez-Sanchez L Molecules. 2024; 29(18).

PMID: 39339471 PMC: 11434384. DOI: 10.3390/molecules29184476.


Intestinal microbial diversity of swines fed with different sources of lithium.

de Souza Lopes L, da Silva J, da Luz J, da Silva M, Lima H, Rocha G 3 Biotech. 2024; 14(4):102.

PMID: 38464613 PMC: 10917731. DOI: 10.1007/s13205-024-03938-3.


The Epithelial to Mesenchymal Transition in Colorectal Cancer Progression: The Emerging Role of Succinate Dehydrogenase Alterations and Succinate Accumulation.

Turano M, Vicidomini R, Cammarota F, DAgostino V, Duraturo F, Izzo P Biomedicines. 2023; 11(5).

PMID: 37239099 PMC: 10216699. DOI: 10.3390/biomedicines11051428.


Lithium: A Promising Anticancer Agent.

Villegas-Vazquez E, Quintas-Granados L, Cortes H, Carmen M, Leyva-Gomez G, Rodriguez-Morales M Life (Basel). 2023; 13(2).

PMID: 36836894 PMC: 9966411. DOI: 10.3390/life13020537.


Lithium in Cancer Therapy: Friend or Foe?.

Yang C, Zhu B, Zhan M, Hua Z Cancers (Basel). 2023; 15(4).

PMID: 36831437 PMC: 9954674. DOI: 10.3390/cancers15041095.


References
1.
Du C, Jaggi M, Zhang C, Balaji K . Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin. Cancer Res. 2009; 69(3):1117-24. DOI: 10.1158/0008-5472.CAN-07-6270. View

2.
Jope R . Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci. 2003; 24(9):441-3. DOI: 10.1016/S0165-6147(03)00206-2. View

3.
Peeters M, Price T, Cervantes A, Sobrero A, Ducreux M, Hotko Y . Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28(31):4706-13. DOI: 10.1200/JCO.2009.27.6055. View

4.
Martenson Jr J, Willett C, Sargent D, Mailliard J, Donohue J, Gunderson L . Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol. 2004; 22(16):3277-83. DOI: 10.1200/JCO.2004.01.029. View

5.
Forlenza O, De-Paula V, Diniz B . Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem Neurosci. 2014; 5(6):443-50. PMC: 4063497. DOI: 10.1021/cn5000309. View